OPKO Health (NASDAQ:OPK) versus Forte Biosciences (NASDAQ:FBRX) Head to Head Contrast

Forte Biosciences (NASDAQ:FBRX) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Forte Biosciences and OPKO Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	0	0	3	0	3.00
OPKO Health	0	1	3	0	2.75

Forte Biosciences currently has a consensus target price of $32.50, suggesting a potential upside of 314.01%. OPKO Health has a consensus target price of $2.75, suggesting a potential upside of 106.77%. Given Forte Biosciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Forte Biosciences is more favorable than OPKO Health.

Volatility and Risk

Forte Biosciences has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Earnings & Valuation

This table compares Forte Biosciences and OPKO Health”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$31.48 million	($16.29)	-0.48
OPKO Health	$689.41 million	1.53	-$188.86 million	($0.07)	-19.00

Forte Biosciences has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by company insiders. Comparatively, 49.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Forte Biosciences and OPKO Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-151.43%	-118.92%
OPKO Health	-18.65%	-9.76%	-6.46%

Summary

Forte Biosciences beats OPKO Health on 7 of the 12 factors compared between the two stocks.

About Forte Biosciences

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.